Elevation of serum thioredoxin in patients with gefitinib-induced interstitial lung disease.
OBJECTIVE
Interstitial lung disease (ILD) is a severe adverse event of gefitinib therapy. However, the mechanism still remains unclear. The objective of this study was to examine whether or not oxidative stress, one of the common factors in drug-associated ILD, is involved in the pathogenesis of gefitinib-induced ILD.


METHODS
Using an enzyme-linked immunosorbent assay (ELISA), we measured the concentration of serum thioredoxin (Trx), a redox-active protein with antioxidative effects, in 44 patients treated with gefitinib, including three patients who had ILD.


RESULTS
In patients who had gefitinib-induced ILD, serum Trx levels were significantly elevated. They decreased after cessation of gefitinib therapy accompanying clinical improvement of ILD.


CONCLUSIONS
It was suggested that oxidative stress may be involved as a part of mechanisms causing or worsening gefitinib-induced ILD.
Sakuma
Keiichiro
K
Department of Respiratory Medicine, Kyoto University Graduate School of Medicine, Kyoto. ksakuma@aichi-cc.jp
Nakamura
Hajime
H
Nakamura
Takayuki
T
Hoshino
Yuma
Y
Ueda
Shugo
S
Ichikawa
Masataka
M
Tabata
Chiharu
C
Fujita
Shiro
S
Masago
Katsuhiro
K
Yodoi
Junji
J
Mishima
Michiaki
M
Mio
Tadashi
T
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D000077156:Gefitinib; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000097:blood* / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress / Q000187:drug effects; D011799:Quinazolines / Q000009:adverse effects*; D013879:Thioredoxins / Q000097:blood*
D000970:Antineoplastic Agents; D011799:Quinazolines; D013879:Thioredoxins; D000077156:Gefitinib